Close Window

Digital Look Email A Friend

Faron upbeat on updated data from cancer treatment study

Published by Josh White on 23rd February 2022

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced updated survival data from the phase 1 and 2 study investigating the safety and efficacy of 'bexmarilimab' on Wednesday.


Email this article to your friends
NOTE: These email addresses will be used to email the information on your behalf and will not be collected by Digital Look for any marketing purposes.